53 related articles for article (PubMed ID: 17202700)
21. (E)-1-(3,4-Dimeth-oxy-phen-yl)-3-[4-(methyl-sulfan-yl)phen-yl]prop-2-en-1-one.
Fun HK; Asik SI; Lobo PL; Prasad DJ; Bojapoojary
Acta Crystallogr Sect E Struct Rep Online; 2011 Sep; 67(Pt 9):o2403. PubMed ID: 22058995
[TBL] [Abstract][Full Text] [Related]
22. 1-(2-Hy-droxy-4-meth-oxy-phen-yl)-3-(4-methyl-phen-yl)prop-2-en-1-one.
Thippeswamy GB; Vijay Kumar D; Jayashree BS; Sridhar MA; Shashidhara Prasad J
Acta Crystallogr Sect E Struct Rep Online; 2011 Apr; 67(Pt 4):o829. PubMed ID: 21754113
[TBL] [Abstract][Full Text] [Related]
23. Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery.
Ekins S; Freundlich JS; Choi I; Sarker M; Talcott C
Trends Microbiol; 2011 Feb; 19(2):65-74. PubMed ID: 21129975
[TBL] [Abstract][Full Text] [Related]
24. Chalcones and flavonoids as anti-tuberculosis agents.
Lin YM; Zhou Y; Flavin MT; Zhou LM; Nie W; Chen FC
Bioorg Med Chem; 2002 Aug; 10(8):2795-802. PubMed ID: 12057669
[TBL] [Abstract][Full Text] [Related]
25. QSAR of Chalcones Utilizing Theoretical Molecular Descriptors.
Nandi S; Bagchi MC
Curr Comput Aided Drug Des; 2015; 11(2):184-93. PubMed ID: 26135340
[TBL] [Abstract][Full Text] [Related]
26. Syntheses of lipophilic chalcones and their conformationally restricted analogues as antitubercular agents.
Ahmad I; Thakur JP; Chanda D; Saikia D; Khan F; Dixit S; Kumar A; Konwar R; Negi AS; Gupta A
Bioorg Med Chem Lett; 2013 Mar; 23(5):1322-5. PubMed ID: 23369537
[TBL] [Abstract][Full Text] [Related]
27. DFT-based QSAR models to predict the antimycobacterial activity of chalcones.
Barua N; Sarmah P; Hussain I; Deka RC; Buragohain AK
Chem Biol Drug Des; 2012 Apr; 79(4):553-9. PubMed ID: 22151277
[TBL] [Abstract][Full Text] [Related]
28. Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques.
Roy K; Roy PP
Eur J Med Chem; 2009 May; 44(5):1941-51. PubMed ID: 19110342
[TBL] [Abstract][Full Text] [Related]
29. QSAR studies on chalcones and flavonoids as anti-tuberculosis agents using genetic function approximation (GFA) method.
Sivakumar PM; Geetha Babu SK; Mukesh D
Chem Pharm Bull (Tokyo); 2007 Jan; 55(1):44-9. PubMed ID: 17202700
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic correlation of structurally modified chalcone derivatives as promising leads to treat tuberculosis.
Sabarathinam S; Ganamurali N; Satheesh S; Dhanasekaran D; Raja A
Future Med Chem; 2023 Oct; 15(20):1903-1913. PubMed ID: 37877262
[TBL] [Abstract][Full Text] [Related]
31. Chalcones in cancer: understanding their role in terms of QSAR. II part.
Repanas A; Katsori AM; Hadjipavlou-Litina D
Mini Rev Med Chem; 2013 Jun; 13(7):952-70. PubMed ID: 22876949
[TBL] [Abstract][Full Text] [Related]
32. Antiangiogenic Effect of Flavonoids and Chalcones: An Update.
Mirossay L; Varinská L; Mojžiš J
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271940
[TBL] [Abstract][Full Text] [Related]
33. QSAR based therapeutic management of M. tuberculosis.
Ahamad S; Rahman S; Khan FI; Dwivedi N; Ali S; Kim J; Imtaiyaz Hassan M
Arch Pharm Res; 2017 Jun; 40(6):676-694. PubMed ID: 28456911
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
